The global genomic biomarker market is predicted to grow at a CAGR of 8.9% from 2023 to 2028 and the market size is predicted to grow from USD 5259 million in 2023 to USD 8054 million by 2028.
MARKET DRIVERS:
The growing number of initiatives from the governments of various countries around genetic research and the rising emphasis on the availability of personalized medicine for enabling improved patient care primarily drive the growth of the genomic biomarker market. The availability of personalized medicines enables better patient care along propels the global market growth. The growing patient population suffering from chronic diseases such as cancer, cardiovascular diseases, diabetes and neurodegenerative disorders contributes to the global market growth. Genomic biomarkers enable researchers and healthcare professionals to identify specific genetic variations and this helps to develop targeted therapies and personalized medicine that lead to better patient outcomes. As genomic biomarkers play an important role in early disease detection and analyzing risk associated with diseases by analyzing an individual’s genetic profile, healthcare providers can identify individuals at a higher risk of developing certain chronic diseases. This enables proactive interventions, lifestyle modification and preventive measures to mitigate the risk early when treatment outcomes are generally more favorable.
The growing number of R&D activities around genomic biomarkers by the key market participants further fuels the growth rate of the market. New genetic biomarkers linked to a variety of diseases are the focus of research and development initiatives. With the use of new genomic technologies such as high-throughput genotyping and next-generation sequencing, researchers may now more precisely and quickly find novel biomarkers. The number of genetic biomarkers that can be utilized for diagnosis, prognosis, and prediction is growing because of these studies. This research activity helped pharmaceutical companies to develop targeted therapies associated with genetic abnormalities and disorders.
Factors such as technological advancements, an increasing number of product launches, a growing number of strategic collaborations between the market participants, the rise in the development of clinical laboratory tests, rise in the ovarian and gastric cancer and the rising burden of chronic diseases support the growth rate of the genomic biomarker market.
MARKET RESTRAINTS:
The drawbacks associated with the utility and analysis of genomic biomarkers are one of the major factors hampering the global market growth. Some genomic biomarkers, such as miRNA present in stool samples, cannot be used as a diagnostic tool for the detection of colon cancer due to concerns regarding the stability of biomarkers and failure to establish predictive value for diagnosing colon cancer. The reimbursement challenges and limited market capabilities in underdeveloped regions further hinder the growth of the genomic biomarker market. The use of genetic biomarker tests and associated services is greatly influenced by reimbursement. Distinct nations and healthcare systems have distinct reimbursement rules and procedures. It may be difficult for healthcare professionals to furnish these tests or for patients to obtain them in some circumstances because reimbursement may not fully cover the costs involved with genetic biomarker testing. The reimbursement that is too little can deter healthcare providers from spending money on genetic biomarker testing and delay the widespread implementation of these technologies.
Impact of COVID-19 on the genomic biomarker market:
The COVID-19 pandemic situation has hampered every sector of the world. The COVID-19 pandemic situation has positively impacted the genomic biomarker market. During the COVID-19 pandemic, as there were rising incidences of cardiovascular diseases, arthritis, and neurological diseases associated with the virus infection, the demand for genomic biomarkers has fuelled and contributed to the global genomic biomarker market growth. According to a report published by the National Center for Biotechnology and Information in January 2021, approximately 6% had ischemic stroke and 0.6% had hemorrhagic stroke. These rising incidences impacted the overall growth of the genomic biomarker market favorably. Genomic biomarkers are used as a diagnostic tool for detecting diseases associated with coronavirus infection and the COVID-19 pandemic crisis has positively impacted the global genomic biomarker market.
REPORT COVERAGE:
|
REPORT METRICS |
DETAILS |
|
Market size available |
2022-2028 |
|
Base year |
2022 |
|
Forecast period |
2023-2028 |
|
Segment covered |
Based on Indication, end-user and geography. |
|
Various analyses covered |
Global, regional, country level analysis, segment level analysis, drivers, restraints, Opportunities, challenges, PESTEL analysis, Competitive landscape. |
|
Regions covered |
North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. |
This research report on the genomic biomarker market has been segmented and sub-segmented based on the Indication, end-user, and region.
Genomic Biomarker Market – By Indication:
Based on indication, the oncology segment is anticipated to account for the leading share of the global market during the forecast period. As there is a rising number of cancer patients globally along with the emerging technological advancement in biomarkers technique, these genomic biomarkers have had several potential applications in oncology, including risk assessment, determination of prognosis, screening of differential diagnosis, monitoring of cancer progression, and prediction of response to treatment. The WHO also estimated that 20.1 million new cancer cases and 9.8 million cancer deaths were reported globally in 2022.
The CVDs segment is estimated to witness a healthy CAGR in the global market during the forecast period. The growing patient population of cardiovascular diseases and the remarkable application of genomic biomarkers in ischemic heart diseases drive the growth of the CVDs segment in the global genomic biomarker market. The rising prevalence of cardiovascular diseases directly impacts the demand for genomic biomarkers as they provide access to reliable health intervention with high-quality control.
Genomic Biomarker Market – By End-User:
Based on end-users, the diagnostic segment is anticipated to hold the largest share of the global market during the forecast period. Factors such as the use of genomic biomarkers for the effective diagnosis of multiple diseases, such as cancer, infectious diseases, neurological disorders, and cardiovascular disorders, are on the rise. Genomic biomarkers are used to examine efficacy or screen for adverse impacts in model systems before human testing. Such factors are expected to boost the growth of the diagnostics segment in the global market.
The hospital segment is estimated to account for a substantial share of the global market during the forecast period. Factors such as the expanding availability of genetic biomarkers in hospitals, rising government spending on healthcare and numerous hospital programs that treat chronic diseases propel the growth of the hospital segment in the global market. For instance, the Centers for Medicare & Medicaid Services (CMS) estimates that American national health spending will increase by an average of 7.5% annually from 2023 to 2028 and will reach around USD 7.2 trillion in that year.
Genomic Biomarker Market – By Region:
North America is anticipated to dominate the market among all regions in the global market during the forecast period. The presence of key market participants and an increasing number of partnerships, acquisitions and collaboration activities between the major market players drive the growth of the genomic biomarker market in the North American region. For instance, American genomic technology provider Gene Centric Therapeutics Inc. announced in August 2022 that it had teamed up with American pharmaceutical company Janssen Research & Development, LLC to create a novel, simple RNA-based genomic biomarker for the detection of bladder cancer.
The European region is expected to register a healthy CAGR in the global market during the forecast period. The growth of the genomic biomarker market in the European region is majorly driven by the presence of notable market players, favorable reimbursement systems and increasing improvements in the healthcare infrastructure across the European region. These factors make it easier for healthcare professionals and patients to use and commercialize genetic biomarker testing, assuring their accessibility.
The Asia-Pacific region is predicted to showcase the fastest CAGR among all regions in the global market during the forecast period. The rapid growth of healthcare infrastructure initiatives in the Asian economy and the significant presence of extremely cutting-edge research facilities in developing nations such as China, India, and Japan are predicted to fuel the need for biomarkers and propel the APAC market growth. The research includes several Asian countries such as South Korea, Malaysia, India, Indonesia and others to capture the widest range of genetic variation.
The Latin American region is expected to grow the market at a healthy CAGR during the forecast period. To speed up scientific progress in the field of genomics, Latin American countries have been making investments in research and development of genomics. This includes the creation of genomics research facilities, partnerships with international organizations, and financial support for genomic investigations. Such investments are helping with the identification of novel genetic biomarkers and the subsequent commercialization of those biomarkers.
The Middle East and Africa is projected to grow at a moderate CAGR in the global market during the forecast period.
KEY MARKET PLAYERS:
Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Liquid Genomics, Inc., AROS Applied Biotechnology A/S, Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Genomic Health, Bio-Rad Laboratories, Inc., Epigenetics AG, and Aepodia are some of the major players in the global market.
RECENT DEVELOPMENT IN THE MARKET:
Frequently Asked Questions
The global genomic biomarker market size is expected to be valued at USD 4829 million in 2022.
The growing number of advancements in genomics research, increasing demand for personalized medicine and growing applications in oncology drive the growth of the genomic biomarkers market.
Thermo Fisher Scientific, Illumina, Qiagen, and Roche are some of the major companies in the global genomic biomarker market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region